JP2014519317A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014519317A5 JP2014519317A5 JP2014509818A JP2014509818A JP2014519317A5 JP 2014519317 A5 JP2014519317 A5 JP 2014519317A5 JP 2014509818 A JP2014509818 A JP 2014509818A JP 2014509818 A JP2014509818 A JP 2014509818A JP 2014519317 A5 JP2014519317 A5 JP 2014519317A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- sequence
- seq
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000282326 Felis catus Species 0.000 claims description 33
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 20
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 20
- 229940053128 nerve growth factor Drugs 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 125000000539 amino acid group Chemical group 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 9
- 241000282324 Felis Species 0.000 claims description 8
- 208000002193 Pain Diseases 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 241000894007 species Species 0.000 claims description 5
- 230000001404 mediated effect Effects 0.000 claims description 3
- 239000012636 effector Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 45
- 239000012634 fragment Substances 0.000 claims 17
- 108091008604 NGF receptors Proteins 0.000 claims 3
- 101150111783 NTRK1 gene Proteins 0.000 claims 3
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims 3
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010036030 Polyarthritis Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 208000030428 polyarticular arthritis Diseases 0.000 claims 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 1
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 3
- 230000007774 longterm Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161483488P | 2011-05-06 | 2011-05-06 | |
| US61/483,488 | 2011-05-06 | ||
| US201161531439P | 2011-09-06 | 2011-09-06 | |
| US61/531,439 | 2011-09-06 | ||
| PCT/GB2012/051003 WO2012153122A1 (en) | 2011-05-06 | 2012-05-08 | Anti-nerve growth factor antibodies and methods of preparing and using the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014519317A JP2014519317A (ja) | 2014-08-14 |
| JP2014519317A5 true JP2014519317A5 (enExample) | 2016-07-21 |
| JP6258194B2 JP6258194B2 (ja) | 2018-01-10 |
Family
ID=46168540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014509818A Active JP6258194B2 (ja) | 2011-05-06 | 2012-05-08 | 抗神経成長因子抗体並びに前記の製造及び使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9328164B2 (enExample) |
| EP (2) | EP2705055B1 (enExample) |
| JP (1) | JP6258194B2 (enExample) |
| KR (2) | KR101783929B1 (enExample) |
| CN (1) | CN103732621B (enExample) |
| AU (1) | AU2012252152B2 (enExample) |
| BR (1) | BR112013028655B1 (enExample) |
| ES (1) | ES2704037T3 (enExample) |
| GB (1) | GB2504887B (enExample) |
| MY (1) | MY161394A (enExample) |
| RU (1) | RU2640254C2 (enExample) |
| SG (2) | SG10201500953YA (enExample) |
| WO (1) | WO2012153122A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| MX359070B (es) | 2010-12-01 | 2018-09-13 | Alderbio Holdings Llc | Composiciones anti-ngf y uso de las mismas. |
| GB2528401A (en) | 2011-05-06 | 2016-01-20 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of preparing and using the same |
| GB201114858D0 (en) | 2011-08-29 | 2011-10-12 | Nvip Pty Ltd | Anti-nerve growth factor antibodies and methods of using the same |
| US9499621B2 (en) | 2013-04-08 | 2016-11-22 | Cytodyn, Inc. | Felinized antibodies and methods of treating retroviral infections in felines |
| BR112016014284A2 (pt) | 2013-12-20 | 2017-12-05 | Intervet Int Bv | anticorpo caninizado isolado ou um fragmento de ligação de antígeno do mesmo, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição farmacêutica, e, métodos para aumentar a atividade de uma célula imune e para produzir um anticorpo caninizado ou fragmento de ligação de antígeno do mesmo |
| US10550194B2 (en) | 2014-09-30 | 2020-02-04 | Intervet Inc. | PD-L1 antibodies binding canine PD-L1 |
| MY184164A (en) * | 2015-05-22 | 2021-03-24 | Astellas Pharma Inc | Novel anti-human ngf antibody fab fragment |
| PT3390451T (pt) | 2015-12-18 | 2025-03-12 | Intervet Int Bv | Anticorpos humanos caninizados para il-4r alfa humano e canino |
| US11091556B2 (en) | 2015-12-18 | 2021-08-17 | Intervet Inc. | Caninized human antibodies to human IL-4R alpha |
| CN115850489A (zh) * | 2016-08-15 | 2023-03-28 | 国立大学法人北海道大学 | 抗pd-1抗体 |
| CN109790533B (zh) * | 2016-08-15 | 2023-04-04 | 国立大学法人北海道大学 | 抗pd-l1抗体 |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| CN111819197B (zh) * | 2018-03-12 | 2025-03-11 | 硕腾服务有限责任公司 | 抗ngf抗体及其方法 |
| GB2578867A (en) * | 2018-10-09 | 2020-06-03 | Genome Res Ltd | Animal models and therapeutic molecules |
| CN110283246A (zh) * | 2019-06-20 | 2019-09-27 | 长春西诺生物科技有限公司 | 一种抗猫细小病毒的猫源化基因工程抗体 |
| US20220324960A1 (en) * | 2019-08-29 | 2022-10-13 | Kindred Biosciences, Inc. | Anti-IL31 Antibodies for Veterinary Use |
| WO2021176362A1 (en) * | 2020-03-03 | 2021-09-10 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| JP2023534636A (ja) | 2020-07-10 | 2023-08-10 | インベテックス インコーポレイテッド | 治療薬のネコにおける半減期を増加させるための組成物及びその使用方法 |
| JP2024518081A (ja) | 2021-05-12 | 2024-04-24 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｒａｎｋｌとｎｇｆに特異的に結合する抗原結合分子およびその医薬用途 |
| CA3229838A1 (en) * | 2021-08-31 | 2023-03-09 | Scout Bio, Inc. | Antigen-binding molecules and uses thereof |
| EP4642796A2 (en) | 2022-12-27 | 2025-11-05 | Invetx, Inc. | Polypeptides with altered binding to neonatal fc receptor (fcrn) and methods of use |
| WO2024155982A2 (en) | 2023-01-20 | 2024-07-25 | Invetx, Inc. | Bispecific binding agents for use in companion animals |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| CA2022959C (en) * | 1989-08-10 | 2001-03-20 | Hiroaki Maeda | Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin |
| AU2238292A (en) | 1991-06-14 | 1993-01-12 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
| GB9202796D0 (en) | 1992-02-11 | 1992-03-25 | Wellcome Found | Antiviral antibody |
| SE9400088D0 (sv) | 1994-01-14 | 1994-01-14 | Kabi Pharmacia Ab | Bacterial receptor structures |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| AU2001253282A1 (en) | 2000-04-07 | 2001-10-23 | Heska Corporation | Compositions and methods related to canine igg and canine il-13 receptors |
| US7417130B2 (en) | 2000-09-08 | 2008-08-26 | University Of Zurich | Collection of repeat proteins comprising repeat modules |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
| US20030190705A1 (en) | 2001-10-29 | 2003-10-09 | Sunol Molecular Corporation | Method of humanizing immune system molecules |
| WO2003060080A2 (en) | 2001-12-21 | 2003-07-24 | Idexx Laboratories, Inc. | Canine immunoglobulin variable domains, caninized antibodies, and methods for making and using them |
| KR20050111598A (ko) | 2003-02-19 | 2005-11-25 | 리나트 뉴로사이언스 코퍼레이션 | 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물 |
| ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| JP5301152B2 (ja) * | 2004-04-07 | 2013-09-25 | ライナット ニューロサイエンス コーポレイション | 神経成長因子アンタゴニストを投与することによって骨癌の疼痛を処置するための方法 |
| US7462697B2 (en) | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| ITRM20050290A1 (it) * | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| US20070191272A1 (en) | 2005-09-27 | 2007-08-16 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| DK2243829T3 (da) * | 2008-01-11 | 2014-11-17 | Astellas Pharma Inc | Forbedret humaniseret anti-humant alfa-9-integrin-antistof |
| WO2010027488A2 (en) * | 2008-09-04 | 2010-03-11 | Vet Therapeutics, Inc. | Monoclonal antibodies |
| US20110300068A1 (en) * | 2009-01-12 | 2011-12-08 | Takeda Pharmaceutical Company Limited | Agent for prophylaxis or treatment of cancer |
| WO2010110838A2 (en) | 2009-03-25 | 2010-09-30 | Vet Therapeutics Inc. | Antibody constant domain regions and uses thereof |
| WO2010117448A2 (en) | 2009-04-05 | 2010-10-14 | Provenance Biopharmaceuticals Corp. | Chimeric immunocytokines and methods of use thereof |
| JP6121903B2 (ja) | 2010-08-19 | 2017-04-26 | ゾエティス・ベルジャム・エス・アー | 抗ｎｇｆ抗体およびその使用 |
| US9968693B2 (en) * | 2013-10-23 | 2018-05-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Small molecule imaging of fungi by positron emission tomography scanning |
-
2012
- 2012-05-08 KR KR1020137032544A patent/KR101783929B1/ko active Active
- 2012-05-08 MY MYPI2013702080A patent/MY161394A/en unknown
- 2012-05-08 JP JP2014509818A patent/JP6258194B2/ja active Active
- 2012-05-08 EP EP12723731.1A patent/EP2705055B1/en active Active
- 2012-05-08 US US14/115,787 patent/US9328164B2/en active Active
- 2012-05-08 EP EP18205428.8A patent/EP3498732B1/en active Active
- 2012-05-08 KR KR1020177016066A patent/KR20170070272A/ko not_active Ceased
- 2012-05-08 SG SG10201500953YA patent/SG10201500953YA/en unknown
- 2012-05-08 GB GB1320046.4A patent/GB2504887B/en active Active
- 2012-05-08 AU AU2012252152A patent/AU2012252152B2/en active Active
- 2012-05-08 CN CN201280033596.4A patent/CN103732621B/zh active Active
- 2012-05-08 SG SG2013081898A patent/SG194793A1/en unknown
- 2012-05-08 ES ES12723731T patent/ES2704037T3/es active Active
- 2012-05-08 BR BR112013028655-5A patent/BR112013028655B1/pt active IP Right Grant
- 2012-05-08 WO PCT/GB2012/051003 patent/WO2012153122A1/en not_active Ceased
- 2012-05-08 RU RU2013154301A patent/RU2640254C2/ru not_active Application Discontinuation
-
2016
- 2016-03-28 US US15/082,541 patent/US20160272701A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014519317A5 (enExample) | ||
| JP2014519318A5 (enExample) | ||
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP2019147801A5 (enExample) | ||
| JP2013538057A5 (enExample) | ||
| RU2016137256A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
| JP2018506277A5 (enExample) | ||
| JP2012526558A5 (enExample) | ||
| JP2020536532A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2013535952A5 (enExample) | ||
| JP2014527814A5 (enExample) | ||
| JP2017502695A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2019532619A5 (enExample) | ||
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2014522236A5 (enExample) | ||
| JP2016512551A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2016188209A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JP2018517431A5 (enExample) | ||
| JP2018510617A5 (enExample) | ||
| JP2014526898A5 (enExample) | ||
| JP2014530215A5 (enExample) |